Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2020

View Archived Issues

City of Hope begins phase I testing of investigational SARS-CoV-2 vaccine COH-04S1

Altimmune submits IND application with the FDA for phase I study of AdCOVID

Equillium decides not to start phase III study of itolizumab for COVID-19

Kinnate Biopharma patents Raf kinase inhibitors

Constellation Pharmaceuticals synthesizes TREX1 inhibitors

Aclaris Therapeutics identifies new JAK inhibitors

Incyte synthesizes CDK2/cyclin E inhibitors

Bluebird bio divulges non-natural T cells for cancer

InMed reports results from an initial phase I trial of INM-755 healthy subjects

FDA grants accelerated approval to Danyelza for neuroblastoma

Chinese approval for phase I/II study of ATG-016 for MDS

ICT presents a novel CoupledCAR technology against colorectal cancer

Health Canada approves Lynparza as treatment of BRCA or ATM gene-mutated mCRPC

MetrioPharm plans to conduct a phase II study of MP-1032 in patients with COVID-19

Karyopharm presents phase III data from SEAL study of Xpovio in liposarcoma

Targeting lung metastases is EASI way to induce systemic immunity

ADG-2: preclinical results of a neutralizing antibody for human SARS-CoV-2

FDA proposes conduct of additional exploratory analyses for omaveloxolone in Friedreich's ataxia

Senhwa files INDs in U.S. and Canada to study CX-5461 for solid tumors with BRCA2 or PALB2 mutations

Phase I data presented for rCSP-based malaria vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...